Research with stem cell-based embryo models has opened new avenues for studying embryogenesis and its implications to understanding human disorders and diseases. However, science is advancing so rapidly that jurisdictions around the world are struggling with the evolving ethical complexities and boundaries of exploration. This session pulls together experts grappling with the implications of these developments to help us understand the scientific landscape and formulate coherent regulations based on robust ethical and governance discussions around the globe.
This session will provide a high-level overview of regenerative medicine efforts by institution and/or organ.
Many stem cell models now exist for multiple genetic diseases. They are increasingly used for finding therapeutics. Examples of how stem cell models are being used for drug discovery will be shown in this session.
Stem cells sense their environment, process information, and continuously react to stimuli to self-renew or differentiate. In this session, speakers will cover the construction of synthetic gene networks as well as new models of human developmental mechanisms to improve our understanding of stem cell regulatory networks.
This session will explore topics of tissue and organ development primarily through the lens of developmental studies in organisms.
Cell fate transitions, once thought to be irrevocable, are now known to frequently exhibit plasticity. Remarkably, even some terminally differentiated cells can regain the capacity to self-renew when challenged. This session will explore the nature of plasticity in cell fate decisions, pinpoint the contexts in which plasticity is invoked, and dissect its molecular and signaling basis.
Organized by: ISSCR Industry Committee
Human Pluripotent Stem Cell (hPSC)-derived cell therapies are now being investigated in clinical trials. Despite 26 years of rigorous basic science with hPSCs, navigating the regulatory landscape for the clinical translation of PSC-derived cell therapies remains challenging due to the complexities of cellular drug products and limited experiences reviewing and approving them. As the leading stem cell society, the ISSCR is in a unique position to share its scientific expertise with global regulators and work with agencies to facilitate improved future regulatory processes for stem cell-based therapies. In this ISSCR Industry Focus Session, the society shares important insights and feedback gleaned from its liaison meetings with regulatory agencies with our community of scientists to ameliorate their chances of IND approvals and inform the development of effective and safe new therapies.
Hear from invited speakers from the various realms of regenerative medicine: ESC- and iPSC-derived cell therapies, gene therapies, and in situ reprogramming.
This session is the capstone of the Annual Meeting and will include the Public Service Award presentation and lectures from the winners of the ISSCR Momentum and Achievement Awards, in addition to the Keynote Address.
ISSCR Public Service Award
Peter W. Andrews, BSc, DPhil, MBA, University of Sheffield, UK
Tenneille E. Ludwig, PhD, WiCell Stem Cell Bank, USA
ISSCR Momentum Award Lecture
Sergiu Paşca, PhD, Stanford University, USA
ISSCR Achievement Award Lecture
Fiona M. Watt, DPhil, FRS, EMBL -Heidelberg, Germany
Melissa H. Little, AC, PhD, Novo Nordisk Foundation Centre for Stem Cell Medicine (reNEW), Denmark, and Murdoch Children’s Research Institute, Australia
.png)
.png)
.png)